Eppendorf Continues Successful Development
News May 03, 2016
The Eppendorf Group concluded fiscal year 2015 with Group sales of €629.1 million (prior year: €531.1 million) and growth in sales of 18.5% (7.1% when adjusted for currency effects). Income from operations (EBIT) climbed 24.7% to €119.3 million (prior year: €95.7 million).
Eppendorf’s growth last year encompassed all its product groups, and the company profited from the positive development of both traditional and new markets. Investments were made in the subsidiaries, including new facilities in Brazil and India, and in the expansion of Eppendorf’s sales structures. 2015 also saw an increase in research and development expenditures to €31.9 million (prior year: €29.4 million).
Thomas Bachmann, Chief Executive Officer of Eppendorf AG, was satisfied with the company’s result: “In 2015 we grew organically at a level well above the industry average of 4 to 5%, which is itself healthy. Significant success factors in our development are our innovative momentum, the high quality of our products, and a staff committed to doing the best for our customers every day. Our investments in sales and in the expansion of our services are also paying off.”
In 2016, the company intends to focus on device and data networking as well as product and application developments. Additional investments in the expansion of the country organizations and the development and production facilities are also planned.
Tight junctions are multi-protein complexes that serve as barriers in epithelial tissues such as the skin or lining of the gut. Loss of a specific tight junction barrier protein, claudin 18, occurs in the majority of gastric cancer patients and is correlated with poor prognosis in patients with advanced gastric cancer.READ MORE
18th International Conference on Pharmaceutics & Novel Drug Delivery Systems
May 27 - May 28, 2019